Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gentler mouthwash could tame gum disease with fewer side effects

NCT ID NCT06967402

Disease control Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two mouthwashes used alongside standard gum disease treatment. One contains a higher dose of chlorhexidine (0.2%), while the other combines a lower dose of chlorhexidine (0.12%) with cetylpyridinium chloride. The goal is to see if the lower-dose combination works just as well at reducing plaque and gum inflammation, but with fewer side effects like staining or taste changes. About 60 adults with severe periodontitis will use the mouthwash for three weeks, and researchers will measure gum bleeding and bacteria levels before and after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
chlorhexidine and cetylpyridinium chloride mouthwash
What this could lead to
If successful, this could offer a gentler mouthwash option for managing severe gum disease, reducing side effects like staining and taste changes.
What could go wrong
This is a small, early-stage trial with only 60 participants, so results may not apply to everyone. The new mouthwash might not be as effective as the standard one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Consenting patients with at least 6 evaluable teeth in each quadrant, including minimum 1 molar and 1 premolar. * Generalized stage II-III periodontitis patients. * Baseline BOP \> 25%. * No known allergy or adverse effects to CHX or CPC * Non-smokers, non-orthodontic patients, no concurrent or past antibiotics/medication known to affect periodontal status (i.e. calcium antagonists, phenytoin)/anti-inflammatory therapy (i.e. NASIDs) in the last 3 months, pregnant/breastfeeding, compliance to study procedures. * ASA class I-II patients. * Either non-diabetic or with controlled diabetes (HbA1C\<7). * Normal/Elevated blood pressure (AHA - Systolic \<130mmHg; Diastolic \<80mmHg). * No radiation/chemotherapy in the past 5 years * No immunosuppression including drug induced immunosuppression. * No participation in other clinical studies in the last 4 weeks. * No administration of CHX or CPC in the last 3 months * No periodontal treatment in the last 3 months. Exclusion Criteria: * Unable to provide written consent. * Non-compliant study procedures. * Patients with medical (including psychiatric) and pharmacotherapeutic histories that, in the investigator's opinion, may compromise the protocol. * Patients requiring antibiotics prophylaxis for dental procedures. * Patients with self-reported pregnancy or patients who are breastfeeding. * Patients with history of use of systemic antibiotics, in combination with any form of periodontal treatment, within the past 3 months. * Patients with uncontrolled endocrine disease. * Patients who are not compliant with the review protocol, leading to deviation of more than 1 week. * Patients requiring the admission of systemic antibiotics, in combination with any form of dental treatment, during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Periodontitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

periodontitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Periodontitis Periodontitis stage II Periodontitis stage III

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • HKU Faculty of Dentistry, IAD - Clinical Research Centre

    RECRUITING

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.